EDAP — Edap Tms S.a.

EDAP TMS Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 HIFU Revenue: EUR 11.7 million, a 34% increase year-over-year (YoY) from EUR 8.8 million in Q4 2024.
• Full Year 2025 HIFU Revenue: EUR 33.1 million, up 39% from EUR 23.8 million in 2024.
• Total Revenue for Q4 2025: EUR 18.9 million, a 7% decline from EUR 20.3 million in Q4 2024, primarily due to a 38% drop in noncore distribution and ESWL businesses.
• Operating Loss: EUR 5.2 million for Q4 2025, compared to EUR 3.7 million in Q4 2024.
• Net Loss: EUR 8.2 million or EUR 0.22 per share, increased from a net loss of EUR 1.9 million or EUR 0.05 per share YoY.
• Gross Margin: 42.6%, down from 44.8% YoY, impacted by tariffs and inventory reserves.

2. Strategic Updates and Business Highlights

• Record Performance: 2025 marked the strongest year for EDAP, particularly in the HIFU segment, with significant growth in system placements and procedure volumes.
• Focal One System Placements: 15 placements in Q4, including 14 cash sales, with notable growth in the U.S. market.
• Regulatory Milestone: Received FDA clearance for the next-generation Focal One Robotic HIFU, enhancing imaging capabilities.
• Clinical Expansion: Advancing into new indications such as endometriosis and BPH, with ongoing clinical trials.
• Reimbursement Landscape: Favorable changes in the 2026 outpatient prospective payment system and physician fee schedule, enhancing the economic viability of HIFU procedures.

3. Forward Guidance and Outlook

• 2026 HIFU Revenue Guidance: Expected to range from USD 50 million to USD 54 million, representing a growth of 34% to 45% over 2025.
• Noncore Revenue Guidance: Anticipated to be between USD 22 million and USD 26 million, reflecting continued decline in noncore segments.
• Growth Drivers: Continued focus on capital sales and procedure volume growth, with expectations for a strong second half of 2026.

4. Bad News, Challenges, or Points of Concern

• Decline in Noncore Revenue: Total revenue decreased by 3% YoY due to a significant drop in noncore distribution and ESWL businesses.
• Operating Losses: Increased operating losses and net losses raise concerns about profitability in the near term.
• Tariff Impact: Ongoing tariffs on imports from France are expected to impact margins, with a budgeted EUR 2.5 million in tariffs for 2026.
• Market Competition: The company is navigating a competitive landscape, particularly in the focal therapy market.

5. Notable Q&A Insights

• Procedure Growth: Management indicated strong growth in procedures, with a 28% increase in Q4 2025 YoY, and no significant impact from external factors like weather events.
• Sales Strategy: Emphasis on cash sales for Focal One systems, with a reduced need for operational leases, reflecting confidence in the product's value.
• Revenue Patterns: Expected seasonal revenue patterns, with Q4 projected as the strongest quarter and Q3 as the lowest due to typical hospital capital expenditure cycles.
• Noncore Business Outlook: Noncore revenue is expected to decline further, with a focus on evaluating the materiality and profitability of remaining distribution agreements.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by EDAP TMS as discussed in the Q4 2025 earnings call.